Prof. Jodar (Madrid, Spain)
- Boehringer Ingelheim
- HCP Portal
- Products
- Trajenta®
- Resources
- Prof. Jodar (Madrid, Spain)
Prof. Jodar (Madrid, Spain)
Published 16.11.2018 by Boehringer Ingelheim
CARMELINA® is a unique CVOT in the DPP4i class as it investigated the long-term cardiovascular and kidney safety profile of linagliptin in T2D patients with high risk of heart and kidney disease.
Transcript
CARMELINA® investigated the long-term cardiovascular and kidney safety profile of linagliptin as compared with placebo in type 2 diabetes patients. In patients with a very, very high risk of heart and kidney disease. Therefore, CARMELINA® is unique cardiovascular outcome trial as compared to other trials. I mean inside in this DPP4 inhibitor class because it also investigated the kidney safety profile of linagliptin in this very special, high-risk population –not only of heart but also of kidney disease.
